CRIS Current Research Information System

MARINELLI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.264
AS - Asia 1.972
EU - Europa 1.389
AF - Africa 145
SA - Sud America 96
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 1
Totale 5.883
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.231
VN - Vietnam 737
SG - Singapore 473
CN - Cina 392
IT - Italia 335
GB - Regno Unito 242
SE - Svezia 192
DE - Germania 174
HK - Hong Kong 114
FR - Francia 84
IN - India 75
NL - Olanda 69
BR - Brasile 66
RU - Federazione Russa 56
IE - Irlanda 51
FI - Finlandia 40
ZA - Sudafrica 40
BD - Bangladesh 37
TG - Togo 35
JP - Giappone 34
UA - Ucraina 34
SC - Seychelles 31
CA - Canada 27
CH - Svizzera 24
PH - Filippine 18
EE - Estonia 17
BG - Bulgaria 16
CI - Costa d'Avorio 15
EU - Europa 15
JO - Giordania 14
KR - Corea 14
TH - Thailandia 14
AR - Argentina 10
AT - Austria 10
BE - Belgio 10
ID - Indonesia 9
NG - Nigeria 9
PL - Polonia 9
ES - Italia 8
IQ - Iraq 7
TW - Taiwan 7
CL - Cile 6
LT - Lituania 6
TR - Turchia 6
CO - Colombia 5
MX - Messico 5
PY - Paraguay 5
MA - Marocco 4
MY - Malesia 4
UZ - Uzbekistan 4
HR - Croazia 3
PE - Perù 3
PK - Pakistan 3
SN - Senegal 3
DZ - Algeria 2
GH - Ghana 2
GR - Grecia 2
KE - Kenya 2
LV - Lettonia 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EG - Egitto 1
GE - Georgia 1
HU - Ungheria 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LC - Santa Lucia 1
MK - Macedonia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.883
Salva come PNG Salva come JPEG
Città #
Singapore 339
Ashburn 266
Dong Ket 217
Southend 214
Fairfield 209
Chandler 185
Ho Chi Minh City 151
San Jose 147
Hanoi 118
Hong Kong 102
Seattle 99
Wilmington 91
Woodbridge 87
Houston 80
Bologna 77
Santa Clara 67
Princeton 56
Cambridge 54
Boardman 53
Dublin 51
Ann Arbor 50
Los Angeles 46
Beijing 36
Lauterbourg 35
Lomé 35
Helsinki 32
New York 31
Da Nang 29
Dallas 29
Council Bluffs 28
Tokyo 27
Padova 24
Westminster 22
Dearborn 21
Frankfurt am Main 21
Berlin 20
Bern 20
Nanjing 20
Haiphong 18
Hefei 18
Jinan 18
Sofia 16
Abidjan 15
Chicago 15
Munich 15
Amman 13
Buffalo 13
Guangzhou 13
Johannesburg 13
Saint Petersburg 13
Turin 13
Nanchang 12
Phoenix 12
Shanghai 12
Florence 11
Jacksonville 11
Redondo Beach 11
São Paulo 11
Toronto 11
Amsterdam 10
Brussels 10
Düsseldorf 10
Abeokuta 9
Changsha 9
Milan 9
Montreal 9
Seoul 9
San Diego 8
Shenzhen 8
Tianjin 8
Bangkok 7
Des Moines 7
Hangzhou 7
Bühl 6
Bến Tre 6
Catanzaro 6
Hebei 6
Medford 6
Naples 6
Nuremberg 6
Palermo 6
Shenyang 6
Thái Bình 6
Warsaw 6
Atlanta 5
Bremen 5
Falkenstein 5
Imola 5
Jakarta 5
Kunming 5
Olalla 5
Orem 5
Paris 5
Redwood City 5
Sassari 5
Turku 5
Vienna 5
Xi'an 5
Zhengzhou 5
Bắc Giang 4
Totale 3.738
Salva come PNG Salva come JPEG
Nome #
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 286
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 271
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma 254
Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study 242
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 241
Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. 240
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 236
Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted? 234
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 221
Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. 215
Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma 211
Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma 202
Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry 198
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: A multicenter real-life study 177
Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients 177
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. 174
Early Prediction of Treatment Response to Sorafenib with Elastosonography in a Mice Xenograft Model of Hepatocellular Carcinoma: A Proof-of-Concept Study. 170
null 164
The role of ultrasound elastographic techniques in chronic liver disease: current status and future perspectives 162
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study 159
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 153
Experience with regorafenib in the treatment of hepatocellular carcinoma 149
Erratum to: Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry (Intern Emerg Med, 10.1007/s11739-016-1416-8) 137
Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases. 132
Ipertensione portale. 132
Letter to the editor. 131
The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: A retrospective multicentre study. 113
Gut microbiome alterations and lenvatinib resistance in hepatocellular carcinoma: the role of Akkermansia muciniphila postbiotics in treatment enhancement 94
Sorafenib versus Y90 radioembolization in cirrhotic patients with hepatocellular carcinoma (HCC): cohort and nested control-case study with propensity analysis 89
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients. 88
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib 86
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC 83
null 77
miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment 73
The tumour suppressor miR-22 induces metabolic reprogramming through GLUT1 targeting and represents a possible biomarker of Sorafenib response in Hepatocellular Carcinoma 66
MiR-22 downregulation activates HIF-1A pathway and induces tumour progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma 63
Neutrophil–lymphocyte ratio is associated with worse outcomes in patients with cirrhosis: insights from the PRO-LIVER Registry 53
MiR-22 regulates HIF-1A pathway and tumor progression and represents a possible biomarker of sorafenib response in hepatocellular carcinoma 51
Totale 6.004
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.636
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.636
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021240 0 0 0 0 0 0 0 0 0 0 0 240
2021/2022612 61 14 24 62 51 33 12 32 18 44 181 80
2022/2023669 79 105 27 94 35 68 16 26 114 14 46 45
2023/2024194 24 25 12 20 15 47 11 4 13 13 6 4
2024/2025629 23 70 73 61 97 32 41 27 10 64 20 111
2025/20262.435 164 133 137 135 244 143 323 144 561 179 133 139
Totale 6.004